TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Cancergenetik i Stockholm AB
Closing information (x1000 EUR)
| Closing information | 2024/03 | 2023/03 | 2022/03 |
| Turnover |
0
|
130
|
195 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
-26
|
27
|
28 |
| EBITDA |
-26
|
27
|
28 |
| Total assets |
48
|
66
|
44 |
| Current assets |
48
|
66
|
44 |
| Current liabilities |
17
|
7
|
2 |
| Equity capital |
31
|
56
|
40 |
| - share capital |
4
|
4
|
5 |
| Employees (average) |
1
|
1
|
1 |
Financial ratios
| Fiscal year | 2024/03 | 2023/03 | 2022/03 |
| Solvency |
64.6%
|
84.8%
|
90.9% |
| Turnover per employee |
0
|
130
|
195 |
| Profit as a percentage of turnover |
20.8%
|
14.4% | |
| Return on assets (ROA) |
-54.2%
|
40.9%
|
63.6% |
| Current ratio |
282.4%
|
942.9%
|
2200% |
| Return on equity (ROE) |
-83.9%
|
48.2%
|
70.0% |
| Change turnover |
-127
|
-49
|
-4 |
| Change turnover % |
-100%
|
-27%
|
-2% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2024/03 | 2023/03 | 2022/03 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.